Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Mappa di calore
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
DOCS
#1292
Doximity, Inc. Class A Common Stock
21.4
0
USD
+1.04%
Settore:
Salute
Base:
USD
Valuta di Profitto:
USD
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
+1.04%
Variazione Mensile
-10.05%
Variazione di 6 mesi
-58.04%
Variazione Annuale
-58.60%
Chiusura Precedente
21.1
8
Open
21.3
8
Minimo
21.2
6
High
21.5
7
Volume
1 617
Mercati
US Stock Market
Salute
DOCS
Apri il grafico completo
Full chart
Financials
Panoramica
Estratto Conto
Statistiche
Trimestrale
Annuale
Conto economico
Bilancio
Liquidità
Valore
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
Totale attivo
1.26 B
1.2 B
1.26 B
1.16 B
1.12 B
Totale passività
181.68 M
178.85 M
161.58 M
177.73 M
172.85 M
Patrimonio netto totale
1.08 B
1.03 B
1.1 B
979.3 M
950.84 M
Totale passività e patrimonio netto
1.26 B
1.2 B
1.26 B
1.16 B
1.12 B
Debito totale
—
—
—
—
—
Indebitamento netto
—
—
—
—
—
Doximity, Inc. Class A Common Stock
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration. The company is based in San Francisco.
Notizie
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
Relazione sugli utili: Dr. Martens Q2 2026 manca le previsioni EPS
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
Dr. Martens registra utili FY26 superiori alle attese, margini in miglioramento
Another Wall Street analyst slashes Doximity stock price outlook
DOCS vs. HIMS: Which Stock Is the Better Value Option?
DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care
BofA taglia il target su Doximity per incertezza sulla crescita
HIMS Stock Dips 14.3% Since Q1 Earnings: Should You Still Hold or Sell?
OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?
Down 25.7% in 4 Weeks, Here's Why Doximity (DOCS) Looks Ripe for a Turnaround